UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/700,424	11/05/2003	Daniel David West		5681
43399 EVELYN M. S	7590 05/12/200 OMMER	EXAMINER		
570 LEXINGTON AVENUE , 17TH FLOOR			ALSTRUM ACEVEDO, JAMES HENRY	
NEW YORK, NY 10022			ART UNIT	PAPER NUMBER
			1616	
			MAIL DATE	DELIVERY MODE
			05/12/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	T				
	Application No.	Applicant(s)			
	10/700,424	WEST, DANIEL DAVID			
Office Action Summary	Examiner	Art Unit			
	JAMES H. ALSTRUM ACEVEDO	1616			
The MAILING DATE of this communication Period for Reply	n appears on the cover sheet with	h the correspondence address			
A SHORTENED STATUTORY PERIOD FOR R WHICHEVER IS LONGER, FROM THE MAILIN - Extensions of time may be available under the provisions of 37 CI after SIX (6) MONTHS from the mailing date of this communicatic - If NO period for reply is specified above, the maximum statutory p - Failure to reply within the set or extended period for reply will, by Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	IG DATE OF THIS COMMUNIC, FR 1.136(a). In no event, however, may a report. Deriod will apply and will expire SIX (6) MONT statute, cause the application to become ABA	ATION. ply be timely filed "HS from the mailing date of this communication. NDONED (35 U.S.C. § 133).			
Status					
1)⊠ Responsive to communication(s) filed on	31 October 2007.				
· ·					
,	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims					
4) ⊠ Claim(s) 1-16 is/are pending in the application 4a) Of the above claim(s) 2-16 is/are without 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) 1 is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction a	drawn from consideration.				
Application Papers					
9) The specification is objected to by the Exa					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for for a) All b) Some * c) None of: 1. Certified copies of the priority docur 2. Certified copies of the priority docur 3. Copies of the certified copies of the application from the International But * See the attached detailed Office action for a	ments have been received. ments have been received in Ap priority documents have been r ureau (PCT Rule 17.2(a)).	oplication No received in this National Stage			
Attachment(s)	_				
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-94) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 	8) Paper No(s).	ummary (PTO-413) /Mail Date formal Patent Application _·			

DETAILED ACTION

Claims 1-16 are pending. Applicant's response to the restriction requirement submitted on October 31, 2007 is acknowledged. Applicant is advised that a new Examiner is examining the instant application.

Election/Restrictions

Applicant's election of Group I in the reply filed on 10/31/2007 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).¹

Claims 2-16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 10/31/2007.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 1 is rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting essential elements, such omission amounting to a gap between the elements. See MPEP § 2172.01. The omitted elements are: (1) hexanes used to extract solanesol from tobacco dust;

¹ Applicant's response did not indicate whether the election was with traverse or without traverse, that it has been assumed that the election was made without traverse.

and (2) the hexane/sodium bisulfite solution utilized in the coupling reaction between 2,3-dimethoxy-5-methylhydroquinone and isodecaprenol to obtain ubiquinone (i.e. coenzyme Q10).

Double Patenting

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

Claim 1 is rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of prior U.S. Patent No. 6,686,485. This is a double patenting rejection.

Other Matter

It is respectfully suggested that Applicant consistently refer to the compound made in the claimed method as either "coenzyme Q10" or ubiquinone in claim 1.

Conclusion

Art made of record and not relied upon is considered pertinent to applicant's disclosure.

U.S. patent No. 6,506,915 (West)² discloses an alternative synthesis of coenzyme Q10 (i.e.

.

² West is not prior art.

Application/Control Number: 10/700,424 Page 4

Art Unit: 1616

ubiquinone) which is a total synthesis beginning with 2,3,4,5-tetramethoxy-6-geranyltoluene as the starting material.

Claim 1 is rejected. No claims are allowed. Claims 2-16 are withdrawn from consideration.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James H. Alstrum-Acevedo whose telephone number is (571) 272-5548. The examiner can normally be reached on M-F, 9:00-6:30, with every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on (571) 272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

J.H.A.-A. Patent Examiner Technology Center 1600

/Johann R. Richter/ Supervisory Patent Examiner, Art Unit 1616